Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
2.42
-0.07 (-2.81%)
Mar 31 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.41 - 2.50
52 week 0.85 - 2.87
Open 2.48
Vol / Avg. 829,754.00/2.54M
Mkt cap 1.34B
P/E     -
Div/yield     -
EPS -0.02
Shares 554.18M
Beta 1.32
Inst. own     -
Apr 1, 2015
Q4 2014 ProMetic Life Sciences Inc Earnings Call - 11:00AM EDT - Add to calendar
Mar 31, 2015
Q4 2014 ProMetic Life Sciences Inc Earnings Release
Feb 9, 2015
ProMetic Life Sciences Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 13, 2015
ProMetic Life Sciences Inc at EBD Biotech Showcase
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -893.17% -84.28%
Operating margin -890.89% -83.64%
EBITD margin - -45.13%
Return on average assets -61.94% -47.76%
Return on average equity -217.55% -122.43%
Employees 159 -
CDP Score - -

Address

440 Armand-Frappier Blvd Suite 300
LAVAL, QC H7V 4B4
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

ProMetic Life Sciences Inc. is a Canada-based biopharmaceutical company. The Company is engaged in bioseparations, plasma-derived therapeutics and small-molecule drug development. The Company operates in two segments which include Protein Technologies and Therapeutics. In-house Therapeutics operating segment has lead compounds, namely PBI-4050 which target unmet medical needs such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segments includes BioTherapeutics- The developer of a validated, state-of-the-art solution for plasma fractionation, the Plasma Protein Purification System; and Bioseparation-Develops and markets bioseparation products based on applications of its patented Mimetic Ligand technology; and Prion Capture/Pathogen Removal. The Company�s subsidiaries include ProMetic BioSciences Inc., ProMetic BioTherapeutics Inc. among others.

Officers and directors

Kym Anthony Independent Chairman of the Board
Pierre Laurin Ph.D. President, Chief Executive Officer, Director
Bruce Pritchard Chief Financial Officer, Chief Operating Officer
Steve J. Burton Chief Executive Officer of ProMetic BioSciences Ltd.
Age: 62
Patrick Sartore General Counsel, Corporate Secretary
John Moran M.D. Chief Medical Officer, Director
Age: 68
Dwun-Hou Chen Ph.D. Senior Vice President, Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Stefan Clulow Director
Charles Kenworthy Director
Age: 56
Bruce J. Wendel Director
Age: 60